MERCK & CO INC
Q1 2025 Form 13-F
Filing Structure
Reports holdings for
- MERCK SHARP & DOHME LLC (not a 13F filer in our records) · since Q4 2024
Key People
Directors & officers from Form 4 filingsDescription and Activity
Merck & Co., Inc. operates primarily in the pharmaceutical and animal health industries. In the pharmaceutical segment, Merck focuses on human health products and vaccines, offering prescription medications such as Keytruda for cancer, Gardasil for HPV prevention, ProQuad, and Januvia for diabetes. The animal health segment provides veterinary pharmaceuticals, vaccines, and health management solutions for both livestock and companion animals. These products are distributed to veterinarians, distributors, farmers, and pet owners.
Merck generates revenue through the sale of its pharmaceutical products and vaccines, with significant contributions from Keytruda, Gardasil, and other treatments. In 2024, pharmaceutical sales accounted for the majority of Merck's $64.17 billion in total sales, with animal health products also contributing to the revenue stream. The primary customers for Merck's products include wholesalers, retailers, hospitals, government agencies, managed health care providers, and individual consumers in the animal health market.
Merck's operational structure includes two main segments: Pharmaceuticals and Animal Health. The company's performance is directly impacted by competition from other pharmaceutical and animal health companies, regulatory pressures, and pricing controls in key markets. Patent protection is vital for its products, and the company relies on a diverse supplier base for raw materials. Additionally, legislative changes, such as those affecting drug pricing, can influence Merck's revenue and profit margins.
Company description summarized from 10-K filing.Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2025 13F record
Q1 2025 13F filing summary
| Period of report | March 31, 2025 |
|---|---|
| Filed | May 14, 2025 |
| Form | 13F-HR |
| Reported value | $164.3M |
| Positions | 12 |
| Change in reported value | -36.3% |
| New positions | 0 |
| Exited positions | 1 |
| Position turnover | 7.7% |
| Top-10 concentration | 99.7% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
13 | $820.3M |
|
Q2 2026 13F
Filed Aug 7, 2026
|
13 | $526.4M |
|
Q1 2026 13F
Filed May 13, 2026
|
14 | $349.4M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
12 | $276.3M |
|
Q3 2025 13F
Filed Nov 12, 2025
|
13 | $228.0M |
|
Q2 2025 13F
Filed Aug 13, 2025
|
13 | $215.6M |
|
Q1 2025 13F
Filed May 14, 2025
|
12 | $164.3M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
13 | $258.0M |
Top 12 holdings · Q1 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | MRNA MODERNA INC | $65.4M | 39.83% |
| 2 | PSNL PERSONALIS INC | $49.3M | 30.01% |
| 3 | KYMR KYMERA THERAPEUTICS INC | $21.1M | 12.86% |
| 4 | TRDA ENTRADA THERAPEUTICS INC | $15.7M | 9.57% |
| 5 | ALEC ALECTOR INC | $4.4M | 2.65% |
| 6 | EVAX EVAXION BIOTECH A/S | $2.2M | 1.37% |
| 7 | STRO SUTRO BIOPHARMA INC | $1.8M | 1.08% |
| 8 | LVTX LAVA THERAPEUTICS NV | $1.5M | 0.89% |
| 9 | VRDN VIRIDIAN THERAPEUTICS INC | $1.3M | 0.77% |
| 10 | XLO XILIO THERAPEUTICS INC | $1.1M | 0.65% |
| 11 | CARM CARISMA THERAPEUTICS INC | $456.7K | 0.28% |
| 12 | NEUP NEUPHORIA THERAPEUTICS INC | $57.8K | 0.04% |
Values as reported on the Q1 2025 Form 13F. Every position is in the holdings table below.